Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Free Cash Flow (2020 - 2025)

Oncology Institute (TOI) has disclosed Free Cash Flow for 6 consecutive years, with -$13.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Free Cash Flow fell 1183.87% year-over-year to -$13.2 million, compared with a TTM value of -$27.5 million through Sep 2025, up 26.61%, and an annual FY2024 reading of -$30.3 million, up 25.82% over the prior year.
  • Free Cash Flow was -$13.2 million for Q3 2025 at Oncology Institute, down from -$11.4 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $2.4 million in Q4 2024 and bottomed at -$24.2 million in Q4 2021.
  • Average Free Cash Flow over 5 years is -$10.4 million, with a median of -$10.5 million recorded in 2022.
  • The sharpest move saw Free Cash Flow plummeted 11501.94% in 2022, then skyrocketed 151.14% in 2024.
  • Year by year, Free Cash Flow stood at -$24.2 million in 2021, then soared by 56.78% to -$10.5 million in 2022, then soared by 54.56% to -$4.8 million in 2023, then soared by 151.14% to $2.4 million in 2024, then tumbled by 644.39% to -$13.2 million in 2025.
  • Business Quant data shows Free Cash Flow for TOI at -$13.2 million in Q3 2025, -$11.4 million in Q2 2025, and -$5.3 million in Q1 2025.